Jaconi M
Biology of Ageing Laboratory, Dept. of Geriatrics, Geneva University Hospitals, Chêne-Bourg, Geneva.
Ther Umsch. 2002 Nov;59(11):588-95. doi: 10.1024/0040-5930.59.11.588.
The capacity of embryonic stem (ES) cells for virtually unlimited self-renewal and differentiation has opened up the prospect of widespread applications in biomedical research and regenerative medicine. The use of these cells would allow to overcome the problems of donor tissue shortage and also implant rejection if the cells are made immunocompatible with the recipient. Since the derivation in 1998 of human ES cell lines from pre-implantation embryos, considerable research is centered on their biology, on how differentiation can be encouraged towards particular cell lineages and also on means to enrich and purify derivative cell types. In addition, ES cells may be used as an in vitro system not only to study cell differentiation but also to evaluate the effects of new drugs and the identification of genes as potential therapeutic targets. This review will summarize what is known about animal and human ES cells with particular emphasis on their application in four animal models of human diseases. Present studies of mouse ES cell transplantation reveal encouraging results but also technical barriers that have to be overcome before clinical trials can be considered.
胚胎干细胞具有几乎无限的自我更新和分化能力,这为生物医学研究和再生医学的广泛应用开辟了前景。如果能使这些细胞与受体具有免疫相容性,那么使用它们将有助于克服供体组织短缺以及移植排斥的问题。自1998年从植入前胚胎中获得人类胚胎干细胞系以来,大量研究聚焦于它们的生物学特性、如何促使其向特定细胞谱系分化,以及富集和纯化衍生细胞类型的方法。此外,胚胎干细胞可作为一种体外系统,不仅用于研究细胞分化,还可用于评估新药的效果以及鉴定作为潜在治疗靶点的基因。本综述将总结关于动物和人类胚胎干细胞的已知信息,特别强调它们在四种人类疾病动物模型中的应用。目前对小鼠胚胎干细胞移植的研究显示出令人鼓舞的结果,但在考虑进行临床试验之前,还必须克服一些技术障碍。